Home > Insider Trading > Filing (0001209191-18-025825)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1718108	Surface Oncology Inc.	SURF	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1732786	S. David Grayzel	C/O Surface Oncology, Inc. 50 Hampshire Street, 8Th Floor Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-04-23	3,181,817	$0.00	4,545,453	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2018-04-23	100,000	$15.00	4,645,453	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2018-04-23	7,000,000	$0.00	3,181,817	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial publicoffering without payment or further consideration and had no expiration date.
The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is AtlasVenture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. The ReportingPerson owns an interest in AVA IX LP and disclaims beneficialownership of the securities held by Atlas Venture Fund IX, except to the extent of his pecuniary interest therein, if any.